Bio-Path Holdings, Inc. (BPTH) — SEC Filings
Bio-Path Holdings, Inc. (BPTH) — 50 SEC filings. Latest: QUALIF (Apr 29, 2026). Includes 35 8-K, 5 10-Q, 2 S-1/A.
View Bio-Path Holdings, Inc. on SEC EDGAR
Overview
Bio-Path Holdings, Inc. (BPTH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a QUALIF filed on Apr 29, 2026: BIO-PATH HOLDINGS, INC. filed a Notice of Qualification (Form QUALIF) on April 28, 2026. This filing indicates the company has met the requirements for qualification, likely related to a securities offering under Regulation A. The company's principal office is located in Bellaire, TX.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 4 bearish, 46 neutral. The dominant filing sentiment for Bio-Path Holdings, Inc. is neutral.
Filing Type Overview
Bio-Path Holdings, Inc. (BPTH) has filed 1 QUALIF, 35 8-K, 5 10-Q, 1 10-K, 2 S-1/A, 2 S-1, 2 SC 13G/A, 1 DEF 14A, 1 SC 13G with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of BPTH's 47 recent filings, 6 were flagged as high-risk, 20 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$7.449M |
| EPS | -$0.97 |
| Debt-to-Equity | N/A |
| Cash Position | $0.0M |
| Operating Margin | N/A |
| Total Assets | $746K |
| Total Debt | $7.904M |
Key Executives
- Dr. Robert L. Smith
- Dr. Michael W. R. Smith
- Dr. David M. E. Chew
- Mr. David M. E. Chew
- Mr. Christopher J. O'Brien
- Peter H. Nielsen
- William R. Rohrlich, II
- M. Ali Panjwani
Industry Context
BIO-PATH HOLDINGS, INC. operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is highly competitive, with companies vying for funding and market share through innovation and clinical trial success. Trends include a focus on novel therapeutics and personalized medicine, but also increasing scrutiny on drug pricing and development efficiency.
Top Tags
financials (10) · sec-filing (8) · 8-k (8) · 8-K (8) · filing (7) · material-agreement (5) · 10-Q (4) · equity-sale (4) · delisting (4) · financial-reporting (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Filing Date | 2026-04-28 | Date of the Notice of Qualification filing |
| File Number | 024-12728 | Associated with the filing |
| Cash | $0.0M | Cash balance at June 30, 2025, down from $1.173M at Dec 31, 2024, indicating severe liquidity issues. |
| Net Loss (Six Months) | $7.449M | Increased from $5.026M in the prior year, reflecting higher operating expenses. |
| Research and Development Expenses (Six Months) | $6.025M | Increased from $4.161M in the prior year, driving higher operating losses. |
| Total Shareholders' (Deficit) Equity | $7.158M | Negative equity at June 30, 2025, a significant decline from positive $154K at Dec 31, 2024. |
| Total Liabilities | $7.904M | Increased from $3.729M at Dec 31, 2024, further straining the balance sheet. |
| Common Shares Outstanding | 8,307,892 | As of August 13, 2025, indicating potential for further dilution if capital is raised. |
| Total Assets | $7.06M | As of March 31, 2025 |
| Net Loss | $1.7M | For the three months ended March 31, 2025 |
| Market Price per Share | 4.12 | Indicates current trading value |
| Market Capitalization | 33.63 | Overall market value of the company |
| Long-term Debt | 1700000 | Financial obligations beyond one year |
| SEC File Number | 333-284363 | Identifies the specific registration filing with the SEC. |
| Stock Price | 33.63 | Appears in filing data, likely related to a specific period. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bio-Path Holdings, Inc. (BPTH)?
Bio-Path Holdings, Inc. has 50 recent SEC filings from Mar 2024 to Apr 2026, including 35 8-K, 5 10-Q, 2 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BPTH filings?
Across 50 filings, the sentiment breakdown is: 4 bearish, 46 neutral. The dominant sentiment is neutral.
Where can I find Bio-Path Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bio-Path Holdings, Inc. (BPTH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bio-Path Holdings, Inc.?
Key financial highlights from Bio-Path Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BPTH?
The investment thesis for BPTH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bio-Path Holdings, Inc.?
Key executives identified across Bio-Path Holdings, Inc.'s filings include Dr. Robert L. Smith, Dr. Michael W. R. Smith, Dr. David M. E. Chew, Mr. David M. E. Chew, Mr. Christopher J. O'Brien and 3 others.
What are the main risk factors for Bio-Path Holdings, Inc. stock?
Of BPTH's 47 assessed filings, 6 were flagged high-risk, 20 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Bio-Path Holdings, Inc.?
Forward guidance and predictions for Bio-Path Holdings, Inc. are extracted from SEC filings as they are enriched.